Working… Menu

Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) (RESCUE-ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04098406
Recruitment Status : Not yet recruiting
First Posted : September 23, 2019
Last Update Posted : September 23, 2019
Clene Australia Pty Ltd
Information provided by (Responsible Party):
Clene Nanomedicine

Brief Summary:
The objective of this trial is to assess the efficacy, safety, and PK/PD effects of CNM-Au8 as a disease-modifying agent for the treatment of ALS by utilizing electrophysiological measures to detect preservation of motor neuron function. The primary endpoint is the mean change in the average difference between active treatment and placebo from Baseline through Week 36 for the MUNIX score(4).

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: CNM-Au8 Drug: Placebo Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Detailed Description:

This is a multi-centre randomised, double-blind, parallel group, placebo-controlled study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who are newly symptomatic within 24-months of Screening and with a clinically probable or possible or definite ALS diagnosis per the Awaji-Shima criteria (de Carvalho et al. 2008).

Patients may be screened over up to a 4-week period. Patients who meet the inclusion criteria and none of the exclusionary criteria will be enrolled into the clinical study.

Patients will be randomised 1:1 into one of two groups: either active treatment with CNM-Au8 30 mg or Placebo.

All patients will receive their randomised oral treatment daily over thirty-six (36) consecutive weeks during the Treatment Period.

There will be three study periods:

  1. Up to a four (4) week screening period (Screening Period);
  2. A thirty-six (36) week blinded randomised treatment period (Treatment Period);
  3. A four (4) week safety follow-up period (End-of-Study Assessment).

Per protocol all patients will receive their blinded and randomised oral treatment daily over at least 36 consecutive weeks during the Treatment Period. Following the end of the Treatment Period patients may be transitioned into an open-label extension period in a separate study protocol (e.g., RESCUE-ALS OLE).

For those patients not transitioning into the separate open-label extension study, patients will complete an EOS safety assessment 4-weeks following study drug discontinuation.

An independent DSMB will be responsible for monitoring the safety of the study on a quarterly basis and ad hoc at the request of the DSMB or the Sponsor (e.g., in the event of unexpected SAEs) to review data throughout the Treatment Period. The DSMB may make recommendations on the conduct of the study, including study termination.

Appropriate procedures will be detailed in a DSMB Charter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized, double-blind, parallel group, placebo-controlled study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The drug formulations will be identical in appearance (size, shape, volume, color) and smell. The packaging and labeling will be designed to maintain blinding to the Investigator's team and to patients. There are no visible differences between the active drug, and placebo dosing units
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS.
Estimated Study Start Date : December 2019
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : June 2021

Arm Intervention/treatment
Placebo Comparator: Placebo
The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatment
Drug: Placebo
Placebo is liquid with identical color and taste

Experimental: 30 mg CNM-Au8
30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
Drug: CNM-Au8
CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.

Primary Outcome Measures :
  1. Mean change in the average difference between active treatment and placebo from baseline for MUNIX (4) score [ Time Frame: 36 weeks ]
    The Motor Unit Number Index (MUNIX) is quantitative neurophysiological method that reflects loss of motor neurons in ALS

Secondary Outcome Measures :
  1. Mean change in the average difference between active treatment and placebo from Baseline as measured by MScanFit MUNE of the Abductor Pollicus Brevis [ Time Frame: 36 weeks ]
    The Motor Unit Number Estimation (MUNE) with compound muscle action potential (MScan) is a non-invasive electrophysiologic method to estimate the number of functioning motor units in a muscle

  2. Mean change in the average difference between active treatment and placebo from Baseline for the MUSIXscore(4) [ Time Frame: 36 weeks ]
    The Motor Unit Size Index (MUSIX) will be reviewed for the Abductor Pollicus Brevis (APB), Abductor Digiti Minimi (ADM), Biceps Brachii (BB), and Tibialis Anterior (TA)

  3. Mean change in the average difference between active treatment and placebo from Baseline for the Neurophysiological Index (NPI) of the ADM [ Time Frame: 36 weeks ]
  4. Mean change in the average difference between active treatment and placebo from Baseline for the Split Hand Index (SI) [ Time Frame: 36 weeks ]

Other Outcome Measures:
  1. Mean change between active treatment and placebo in the proportion of patients experiencing a > 6-point decline in the ALSFRS-R between active treatment and placebo [ Time Frame: 36 weeks ]
  2. Mean change in average ALSFRS-R score [ Time Frame: 36 weeks ]
  3. Mean change in slope of the decline of the ALSFRS-R [ Time Frame: 36 weeks ]
  4. Mean change between active treatment and placebo for the Combined Assessment of Function and Survival (CAFS), a joint-rank analysis of function (ALSFRS-R) and overall survival [ Time Frame: 36 weeks ]
  5. Mean change in the proportion of patients experiencing ALS clinical composite disease progression [ Time Frame: 36 weeks ]
  6. Mean change in rate of disease progression defined as the average change in the FS score ([Max ALSFRS-R minus current ALSFRS-R score]/symptom duration in months) [ Time Frame: 36 weeks ]
  7. Mean change in the average difference between active treatment and placebo for respiratory function as measured by forced vital capacity (FVC) [ Time Frame: 36 weeks ]
  8. Mean change in average difference between active treatment and placebo for the ALSSQOL-Short Form questionnaire (ALSSQOL-SF) [ Time Frame: 36 weeks ]
  9. Mean change in average difference between active treatment and placebo for the Clinician's Global Impression (CGI) [ Time Frame: 36 weeks ]
  10. Mean change in average difference between active treatment and placebo for the Patient's Global Impression (PGI) [ Time Frame: 36 weeks ]
  11. Difference in the proportion of patients utilizing health economic outcome measures [ Time Frame: 36 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Able to understand and give written informed consent.
  2. Male or female patients aged 40 years or greater (inclusive) and less than 80 years of age at the time of ALS diagnosis.
  3. Patients whose conditions are defined as possible or probable or definite ALS per the diagnostic criteria by Awaji-Shima criteria as determined by a neurologist sub-specialising in ALS (e.g., the Principal Investigator by study site).
  4. For patients taking riluzole, stable dosing of riluzole over the prior 30-days from Screening.
  5. At the time of Screening either disease duration less than or equal to 24-months from symptom onset, or disese duration less than or equal to 12-months from diagnosis.
  6. Based on the ENCALS prediction criteria (

    1. Current disease duration ≤ 75% of predicted duration
    2. Predicted 3-month risk of survival at the time of screening ≥ 90%
    3. Predicted 24-month risk of survival at the time of screening ≤ 85%
  7. Forced vital capacity (FVC) 60% of predicted value as adjusted for gender, height, and age at the Screening Visit.
  8. Patient who has established care with a neurologist at one of the specialised ALS clinics involved in the study and will maintain this clinical care throughout the study. If a patient is referred from a third party (neurologist or a State based ALS organisation) they must be willing to transfer care to the neurologist participating in the study.

Exclusion Criteria:

  1. At Screening patients who utilize, or in the Investigator's judgment will be imminently dependent upon:

    1. Non-invasive ventilation > 22 hours per day, or
    2. Tracheostomy Note: If the patient requires non-invasive ventilation post-randomisation, they will be allowed to continue in the study.
  2. Patients with Familial ALS (e.g., 2 or more family members with ALS or motor neuron disease)
  3. Patients with a history of carpal tunnel syndrome, polyneuropathy, or in the investigators judgement diseases that could induce polyneuropathy and interfere with electromyography (EMG) recordings.
  4. Patients with too severe atrophy of the Abductor Digiti Minimi (ADM), Abductor Pollicis Brevis (APB), Biceps Brachii (BB), or Tibialis Anterior (TA) muscles in the least clinically affected hand and leg, respectively, to allow for reliable EMG recordings.
  5. Patient with a history of significant other major medical conditions based on the Investigator's judgment.
  6. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures.
  7. Patient with clinically significant abnormalities in haematology, blood chemistry, ECG, or physical examination not resolved by the Baseline visit which according to Investigator can interfere with study participation.
  8. Patients with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function, or those with low platelet counts (< 150 x 10^9 per liter) or eosinophilia (absolute eosinophil count of ≥ 500 eosinophils per microliter) at Screening.
  9. Patient participating in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening and thereafter).
  10. Females who are pregnant or nursing or who plan to get pregnant during the course of this clinical trial or within 6 months of the end of this trial.
  11. Females of child-bearing potential, or men, who are unwilling or unable to use accepted methods of birth control.
  12. Active inflammatory condition or autoimmune disorder.
  13. Positive screen for drugs of abuse.
  14. History of gold allergy.
  15. Patient is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04098406

Layout table for location contacts
Contact: Robert Glanzman, MD 801-676-9695
Contact: Austin Rynders 801-676-9695

Layout table for location information
Australia, New South Wales
University of Sydney Brain and Mind Centre Not yet recruiting
Sydney, New South Wales, Australia, 2050
Contact: William Hunyh    +61 (2) 9114 4250   
Contact: Eleanor Ramsey, Research coordinator    +61 2 9351 0976   
Westmead Hospital Not yet recruiting
Sydney, New South Wales, Australia, 2145
Contact: Pavarthi Menon, PhD, MD, MBBS, FRACP, MRCP    +61 (2) 8890 8738   
Contact: Julie Ryder, Clinical Research Nurse    +61 (2) 8890 8738   
Sponsors and Collaborators
Clene Nanomedicine
Clene Australia Pty Ltd
Layout table for investigator information
Principal Investigator: Parvarthi Menon, PhD, MD, MBBS Westmead Hospital
Principal Investigator: William Huynh, MD University of Sydney, Brain and Mind Centre

Layout table for additonal information
Responsible Party: Clene Nanomedicine Identifier: NCT04098406     History of Changes
Other Study ID Numbers: CNMAu8.205
First Posted: September 23, 2019    Key Record Dates
Last Update Posted: September 23, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Clene Nanomedicine:
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Disease Progression
Pathologic Processes
Disease Attributes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases